Drug Profile
Muromonab CD3 oral - SciSparc
Alternative Names: aCD3; aCD3 MAb; Anti-CD3 oral immunotherapy; OKT-3 oral - NasVax; Oral anti-CD3 MAb; TRX 318Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Brigham and Womens Hospital
- Developer Therapix Biosciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C; Non-alcoholic steatohepatitis; Type 1 diabetes mellitus; Ulcerative colitis
Most Recent Events
- 28 Jan 2021 Therapix Biosciences is now called SciSparc
- 03 Oct 2016 Discontinued - Phase-II for Hepatitis C in Austria (PO)
- 03 Oct 2016 Discontinued - Phase-II for Hepatitis C in Poland (PO)